- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.04. | G Sachs Adds CHINA RES BEER & India's NTPC to APAC Conviction List; Shionogi & CMS Booted | 100 | AASTOCKS | ||
| 27.02. | PureTech notes positive results from Shionogi's EndeavorRx ADHD trial | 5 | Alliance News | ||
| 27.02. | Shionogi takes Akili's ADHD digital therapy to Japan | 3 | pharmaphorum | ||
| 31.01. | Shionogi & Co. GAAP EPS of ¥435.74, revenue of ¥336.82B | 7 | Seeking Alpha | ||
| 22.12.23 | Juniper Biologics: Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore | 679 | PR Newswire | First drug to show both clinical symptomatic efficacy for five typical Omicron-related symptoms and antiviral efficacy
SINGAPORE, Dec. 21, 2023 /PRNewswire/ -- Singapore-headquartered... ► Artikel lesen | |
| 20.12.23 | Pixie Dust Technologies, Inc.: "Bekämpfen von Demenz mit Klangtherapie"- Pixie Dust Technologies, Shionogi und Shionogi Healthcare entwickeln Gamma-Wellen-Klänge zur Verbesserung der alltäglichen kognitiven Fähigkeiten | 608 | Business Wire | Pixie Dust Technologies, Inc., Shionogi Co. und Shionogi Healthcare Co. haben mit "Memory" und "Tomorrow" zwei Hörerlebnisse auf Basis der Gamma-Wellen-Technologie1 veröffentlicht, die Demenzpatienten... ► Artikel lesen | |
| 20.12.23 | Pixie Dust Technologies, Inc.: "Defy Dementia with Sound." Pixie Dust Technologies, Shionogi and Shionogi Healthcare create Gamma Wave Sound to boost everyday cognitive care. | 743 | Business Wire | Pixie Dust Technologies, Inc., Shionogi Co., Ltd, and Shionogi Healthcare Co., Ltd released "Memory" and "Tomorrow", two audio experiences incorporating gamma wave technology1 designed to provide... ► Artikel lesen | |
| 21.10.23 | F2G, Ltd.: F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TIMM) 2023 Demonstrating Positive Therapeutic Responses in Patients with Invasive Fungal Infections Treated with Oral Olorofim | 718 | GlobeNewswire (Europe) | An overall success rate of 28.7% was seen at day 42, the primary endpoint, and 27.2% at day 84, as determined by a data review committee (DRC) using the EORTC-MSG criteriaThe success rate rose to 75.2%... ► Artikel lesen | |
| 07.09.23 | Shionogi USA: IDWeek 2023: Shionogi and Qpex Biopharma, Inc. Continue Longstanding Commitment to Addressing Unmet Needs in Infectious Disease | 895 | Business Wire | Shionogi Inc., the United States subsidiary of Shionogi Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), announced the upcoming presentation of new data at IDWeek... ► Artikel lesen | |
| 07.06.23 | Aktienmarkt: Shionogi-Aktie kann sich nicht behaupten (41,10 €) | 516 | ARIVA.de | Das Wertpapier von Shionogi notiert heute ein wenig leichter. Der jüngste Kurs betrug 41,10 Euro. Für Inhaber von Shionogi ist der heutige Handelstag bisher nicht sonderlich gut verlaufen. Das Papier... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRULIEVE CANNABIS | 11,360 | -2,07 % | Paukenschlag in USA: Cannabis-Neuregulierung durch DEA sorgt für Kursexplosion! | ||
| WEST PHARMACEUTICAL SERVICES | 338,60 | -0,15 % | West Pharmaceutical Services, Inc. (WST) Q1 2024 Earnings Call Transcript | ||
| HERITAGE CANNABIS | 0,001 | 0,00 % | Heritage Cannabis Announces Commencement of Sale and Investment Solicitation Process | Toronto, ON, April 15, 2024 (GLOBE NEWSWIRE) -- Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) ("Heritage" or the "Company") today announced the commencement of a sale and investment... ► Artikel lesen | |
| SHIONOGI | 43,400 | -1,36 % | Dividendenbekanntmachungen (28.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACOM CO LTD JP3108600002 6 JPY 0,0366 EUR ADVANEX INC JP3213400009 20 JPY 0,1222 EUR AICA KOGYO CO LTD JP3100800006 59 JPY 0... ► Artikel lesen | |
| KALA BIO | 6,150 | -4,06 % | KALA BIO, Inc.: KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | -- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash resources... ► Artikel lesen | |
| CHARLOTTES WEB | 0,181 | -1,63 % | Charlotte's Web Holdings Inc: Charlotte's Web to hold AGSM June 13 | ||
| LUYE PHARMA | 0,344 | -2,27 % | LUYE PHARMA (02186): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 28 MAY 2024 | ||
| BEXIMCO | 0,408 | 0,00 % | EARNINGS AND TRADING: Software Circle & Beximco report higher revenue | ||
| GUARDION HEALTH SCIENCES | 7,250 | 0,00 % | Guardion Health Sciences, Inc. - 8-K, Current Report | ||
| PERCHERON THERAPEUTICS | 0,049 | -2,01 % | PERCHERON THERAPEUTICS LIMITED: WHO selects proposed INN for ATL1102 | ||
| AYURCANN | 0,019 | 0,00 % | Ayurcann verzeichnet Rekordumsatz im 2. Quartal 2024 einschließlich eines 141%igen Anstiegs der Bruttoeinnahmen | Toronto, Ontario, 28. Februar 2024 / IRW-Press / - Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF, FWB:
3ZQ0) ("Ayurcann" oder das "Unternehmen"), ein führendes kanadisches Cannabisextraktionsunternehmen... ► Artikel lesen | |
| MIRUM PHARMACEUTICALS | 24,200 | +0,83 % | Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update | FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2023 and provided a business update.
"2023... ► Artikel lesen | |
| KALBE FARMA | 0,073 | -6,45 % | Allocating IDR 1 trillion, KLBF to set buyback of 625 million shares: PT Kalbe Farma Tbk (KLBF) is allocating ... | ||
| EVEREST MEDICINES | 2,920 | -2,01 % | Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023 | SHANGHAI, March 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing... ► Artikel lesen | |
| AVANT BRANDS | 0,051 | +6,32 % | Avant Brands Inc.: Avant Brands Reports Record Q1 Net Revenue and Outperforms Revenue Guidance | Gross Revenue Outperforms Guidance: Achieved $8.9 million in Gross Revenues, outperforming the guidance range of $8.2 million to $8.7 million.Trending Revenue Growth: Record Net Revenue increased 15%... ► Artikel lesen |
SHIONOGI & CO LTD ADR gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 11,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
